VSVassiliki Sinopoulou

Vassiliki Sinopoulou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vassiliki Sinopoulou has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunomodulators and advanced therapies for maintenance of remission in Crohn’s disease: systematic review and network meta-analysis

    by Vassiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Jane Radford, Gordon William Moran

    Background: With the range of options available for the treatment of Crohn’s disease, therapy selection can be challenging in clinical practice. Comparative efficacy data are needed to clarify the relative position of the increasingly complex portfolio of advanced therapies and guide decision-making. Objectives: Our aim was to compare all advanced and immunomodulator treatments for efficacy and safety in maintenance of remission. Design: Systematic review and network meta-analysis. Data sources and methods: We searched databases up to June 2025. Our outcomes were clinical relapse, loss of response, endoscopic relapse, and safety outcomes. We estimated risk ratio (RR) and 95% confidence interval (CI). We used GRADE to assess certainty of results, and surface under the cumulative ranking curve for ranking treatments. Results: A total of 37 randomised controlled trials with 7415 participants were included. Interventions ranged between 22 weeks and 2 years. Adalimumab probably prevents clinical relapse over placebo (RR 0.68, 95% CI 0.54–0.84, Number Needed to Treat (NNT) = 2, moderate effect magnitude). CT-P13 (RR 0.52, 95% CI 0.38–0.71) and infliximab (RR 0.61, 95% CI 0.49–0.76) may prevent clinical relapse. Upadacitinib is more effective than placebo at preventing loss of clinical response (RR 0.64, 95% CI 0.57–0.72, NNT = 2, small magnitude), while CT-P13 (RR 0.46, 95% CI 0.35–0.53, NNT = 1, large magnitude), natalizumab (RR 0.54, 95% CI 0.43–0.68, NNT = 2, moderate magnitude), certolizumab (RR 0.57, 95% CI 0.47–0.7), NNT = 2, moderate magnitude), adalimumab (RR 0.68, 95% CI 0.61–0.75, NNT = 2, small effect magnitude) and ustekinumab (RR 0.73, 95% CI 0.61–0.86, NNT = 2, small magnitude) probably prevent loss of clinical response. Infliximab (RR 0.7, 95% CI 0.59–0.82) and vedolizumab (RR 0.82, 95% CI 0.68–0.99) may prevent loss of clinical response. Endoscopic relapse could not be analysed. Safety evidence is uncertain, but treatments appear generally safe in the short term. Conclusion: Adalimumab has moderate certainty for maintaining clinical remission with a moderate effect size. Novel therapies seem to have similar effect sizes, though imprecision due to limited evidence precludes further conclusions. Trial registration: https://knowledge.lancashire.ac.uk/id/eprint/53237/

  • Open Access

    Efficacy and acceptability of bowel preparation strategies for inflammatory bowel disease colonoscopy: Systematic review and meta-analysis

    by Gaurav Bhaskar Nigam, Morris Gordon, Vassiliki Sinopoulou, Anukriti Tomar, Shahida Din, Margaret Vance, Ana Wilson, James E East

    Patients with inflammatory bowel disease (IBD) frequently undergo colonoscopy, each requiring bowel preparation. European Society of Gastrointestinal Endoscopy (ESGE) 2019 guidelines recommended high- or low-volume polyethylene glycol (PEG)-based bowel prep for IBD patients; however other non-PEG-based preparations (sulphate and picosulphate-based) have now been studied in IBD. We searched CENTRAL, ClinicalTrials.gov, Embase, MEDLINE, and the World Health Organization International Clinical Trials Registry Platform for randomized controlled trials (RCTs) up to December 2024. Primary outcome was bowel prep success; secondary outcomes included tolerability, acceptability, cecal intubation rates (CIR) and safety. Pooled estimates used risk ratio (RR) and GRADE to assess evidence certainty. Ten RCTs (1479 IBD patients) were included. There was no difference in prep success (relative risk [RR] 0.98, 95% confidence interval [CI] 0.88–1.09; I2 = 33%, 2 RCTs; moderate certainty evidence) between 2 L vs. 4 L PEG, but higher acceptability for 2 L (RR 0.69, 95% CI 0.59–0.80; I2 = 18%, 2 RCTs; high certainty evidence). Low-volume non-PEG vs. PEG are probably similar for prep success (RR 0.96, 95% CI 0.90–1.01; I2 = 6%,3 RCTs; moderate certainty evidence). The evidence on tolerability and acceptability was very uncertain. Subgroup analysis revealed comparable effectiveness of picosulphate-based (RR 0.89, 95% CI 0.78–1.01; I2 = 0%,1 RCT) and sulphate-based preps (RR 0.98, 95% CI 0.91–1.05; I2 = 28%, 2 RCTs) compared with low-volume PEG. Safety data were inconsistently reported. High-certainty evidence supports low-volume PEG as comparably successful to high-volume PEG, with higher acceptability. Moderate-certainty evidence indicates similar success between non-PEG and PEG-based preps. Both low-volume PEG and non-PEG-based preps are supported for use in IBD, broadening options beyond current ESGE guidelines.


  • Open Access

    Immunomodulators and Advanced Therapies for Induction of Remission in Crohn’s Disease: A Systematic Review and Network Meta-Analysis

    by Vasiliki Sinopoulou, Morris Gordon, Shiyao Liu, Daniel Arruda Navarro Albuquerque, Aderonke Ajiboye, Sudheer Kumar Vuyyuru, Shellie Radford, Gordon Moran

    Background: Previous reviews for Crohn’s disease (CD) treatment have rarely considered advanced and immunomodulator medical therapies together. Our aim was to compare all therapies for efficacy and safety in induction of remission. Methods: We searched databases up to June 2025. Our outcomes were clinical remission and response, endoscopic remission, and safety outcomes. We performed network meta-analyses and estimated risk ratios (RR) and 95% CIs. We used GRADE to assess certainty of results, and surface under the cumulative ranking curve for ranking treatments. Results: A total of 79 RCTs with 20 724 participants were included. Interventions ranged from 2 to 30 weeks. There was moderate GRADE certainty of effectiveness over placebo for clinical remission for combination of adalimumab with thiopurines (RR, 2.87; 95% CI, 1.99-4.14; RD (Risk difference) = 35.3%; NNT (Number needed to treat) = 3, large magnitude), guselkumab (RR, 2.5; 95% CI, 1.95-3.21; RD = 28.4%; NNT = 4, moderate magnitude, adalimumab (RR, 2.46; 95% CI, 1.84-3.29; RD = 27.6% NNT = 4, moderate magnitude), combination of infliximab with thiopurines (RR, 2.43; 95% CI, 1.71-3.44; RD = 27%; NNT = 4, moderate magnitude), and ustekinumab (RR, 2.04; 95% CI, 1.69-2.46; RD = 19.6% NNT = 5, small magnitude). For endoscopic remission, there was moderate GRADE certainty of effectiveness for risankizumab (RR, 3.48; 95% CI, 2.18-5.58; RD = 17.4%, moderate magnitude). The certainty on safety varied, but treatments appear generally safe in the short term. Conclusion: Combination of anti-tumor necrosis factors (anti-TNFs) and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have similar effect sizes but with increased imprecision of the estimates.


  • Open Access

    Systematic literature review and meta-analysis on therapeutic management of faecal impaction in the paediatric population

    by Morris Gordon, Svetlana Lakunina, Anna de Geus, Aderonke Ajiboye, Ahmer Khan Amran, Merit Tabbers, Marc A Benninga, Amber Balda, Vassiliki Sinopoulou

    Background: To date, there is no universally accepted or standardised protocol for management of faecal impaction (FI) in paediatric population. If left untreated, it can lead to serious consequences for the health and well-being of the child. We set out to determine the effectiveness and safety of existing therapeutic interventions for FI in children and identify any gaps occurring in current research. Methods: We have performed a systematic literature review on treatment of FI in paediatric population in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We have included randomised controlled trials (RCTs) on all interventions for children (0–18 years old) with FI on background of functional constipation and excluded children with organic causes of FI. Our primary outcomes were treatment success, defecation frequency and withdrawals due to adverse events. We have performed a meta-analysis of the data. Results: Out of 13 341 records identified, only eight RCTs met our inclusion criteria with a total of 513 participants randomised. The diagnosis of functional constipation was mainly made using ROME III criteria. The diagnosis of FI varied from study to study. We identified several intervention groups based on our search. Our analysis has shown that there is no difference probably between PEG (Polyethylene Glycol). and PEG with sodium picosulphate, and there may be no difference between PEG and rectal enema for treatment success, but enema may lead to greater stool frequency. No other studies produced anything other than very low certainty evidence. Conclusions: No therapeutic approach was superior to others, with evidence limited by significant clinical heterogeneity related to varying patient and clinical factors, different outcome measures and limited study numbers. More high-quality research is needed to determine effective strategies for FI. Moreover, a consensus should be reached regarding the definition and diagnosis of FI as based on that a standardised approach to patient’s care can be determined.


  • Open Access

    Faecal impaction in children aged 0–18 years: a systematic review and metanarrative analysis of definitions used

    by Morris Gordon, Amber Balda, Samantha Arrizabalo, Vassiliki Sinopoulou, Stephanie Batarseh, Jina Shargawi, Carlo Di Lorenzo, Marc A Benninga, Merit Tabbers, Miguel Saps

    Background: Faecal impaction is the result of functional constipation in the majority of cases. Surprisingly, a uniform definition for the term faecal impaction is lacking, leading to heterogeneity across study results. Aim: To conduct a metanarrative systematic review to ascertain how trial studies define faecal impaction among children aged 0–18 years with functional constipation. Methods: We conducted a systematic metanarrative review to uncover what criteria are used to define faecal impaction and to recommend directions for creating a globally accepted definition. A comprehensive literature search was conducted using prominent databases, including CENTRAL, MEDLINE, Embase, WHO ICTR (international clinical trials registry) and ClinicalTrials.gov. All relevant publications of RCTs on both faecal impaction and functional constipation from inception to June 2024, including children aged 0–18 years without underlying organic aetiology, were included. Results: 6211 studies were screened, of which 155 were reviewed for eligibility, 76 were included in the review and five are awaiting classification. Seven studies gave an explicit definition, with three referencing a previous consensus definition. 45 studies gave an implicit definition derived from their prescreening or exclusion criteria in a larger piece of research. Clinical assessment was the most common element of definitions, with a mixture of abdominal or rectal assessments reported in 44 studies. A further six studies suggested such clinical assessments are combined with radiographs, and one study reported a definition using radiographs alone. One study reported the duration of symptoms in a definition. Conclusion: There is a clear lack of consensus for defining faecal impaction in children with functional constipation. Despite the clinical, diagnostic and prognostic importance of having a unified definition of faecal impaction, currently there seems to be no universally accepted definition.


  • Top Cited Papers
    Open Access

    ESPGHAN and NASPGHAN 2024 protocol for paediatric functional constipation treatment guidelines (standard operating procedure)

    by Morris Gordon, Anna de Geus, Marcin Banasiuk, Marc A Benninga, Osvaldo Borrelli, Mary Boruta, Anil Darbari, Dawn Dore-Stites, Michelle Gould, Juliette Hawa, et al.

    Introduction: Functional constipation is common in childhood, with chronicity leading to a significant impact on patients and their families. There is a significant range of therapies available to healthcare professionals for this condition, with many novel or recently studied. There is a need for an update to the joint European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) guidelines last released in 2014. We present the prospectively agreed operating procedure and technical review protocol in this manuscript. Methods: ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) will be used for all phases of this guideline development. The Guideline Development Group is formed by paediatric gastroenterologists from both the ESPGHAN as well as the NASPGHAN. A prospective exercise will agree on key outcomes, thresholds of magnitude that are significant at small, moderate and large levels. Systematic evidence searches, selection, extraction, appraisal and analysis will be performed following Cochrane guidance and GRADE guidance for objectively agreeing the certainty of findings. Additional use of network meta-analysis will identify areas of broad triangulation in the evidence. Summary of findings tables will be produced and inform evidence to decision frameworks. These will guide GRADE recommendations with voting to reach a consensus.


  • Open Access

    Towards a definition of refractory/therapy-resistant/intractable constipation in children: a cross-sectional, questionnaire-based, online survey

    by Morris Gordon, Wathsala Hathagoda, Shaman Rajindrajith, Vassiliki Sinopoulou, Mansour Abdulshafea, Carlos Velasco, Merit Tabbers, Marc A Benninga

    Background: The Rome criteria define childhood functional constipation but do not address refractory constipation. Attempts to define refractory constipation lack consensus. The interchangeable use of ‘refractory’ and ‘intractable’ or ‘therapy-resistant’ constipation and lack of understanding of the therapeutic ceilings before this diagnosis complicates the definition.Aim: To conduct an online cross-sectional study among medical professionals and researchers across a range of countries, to propose a consensus definition, terminology and duration of medically unresponsive constipation.Method: An expert-designed questionnaire was disseminated via Google Forms in a two-stage study over 2 months targeting paediatric gastroenterology professionals globally and Latin American clinicians with a translated version. The questionnaire had seven critical questions containing details needed to define medically unresponsive constipation. The study protocol was approved by the ethics review panel.Results: The survey involved 1079 participants: 87 from various countries in the first phase and 992 from Latin America in the second. There were 619 (57.3%) general paediatricians and 462 (43 %) paediatric gastroenterologists. The preferred term to indicate poorly responding constipation was ‘therapy-resistant constipation’ (47.8%), followed by ‘refractory constipation’ (43.6%). The majority of respondents (92.9%) agreed on considering a time frame for defining refractory constipation, with 37.7% suggesting 2–3 months. 467 (43.2%) recommended including failure despite maximum laxative therapy with two agents should be considered as previous therapy failure. Compliance with therapy was deemed essential for successful treatment by 91.1%, assessed through detailed history-taking (47.4%) or medical/pharmacy records (29.4%).Conclusion: Based on the professional views collected in this study, we propose the term ‘therapy-resistant constipation’ and it can be defined as constipation that is not responding to a maximum dose of at least two laxatives of different classes for a minimum of 3 months with good compliance in a secondary or tertiary care facility.


  • Open Access

    Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease

    by Morris Gordon, Gaurav Bhaskar Nigam, Vassiliki Sinopoulou, Ibrahim Al Bakir, Adrian C Bateman, Shahida Din, Sunil Dolwani, Anjan Dhar, O D Faiz, Bu Hayee, et al.

    Introduction The evolving landscape of inflammatory bowel disease (IBD) necessitates refining colonoscopic surveillance guidelines. This study outlines methodology adopted by the British Society of Gastroenterology (BSG) Guideline Development Group (GDG) for updating IBD colorectal surveillance guidelines. Methods and analysis The ‘Grading of Recommendations, Assessment, Development and Evaluation’ (GRADE) approach, as outlined in the GRADE handbook, was employed. Thematic questions were formulated using either the ‘patient, intervention, comparison and outcome’ format or the ‘current state of knowledge, area of interest, potential impact and suggestions from experts in the field’ format. The evidence review process included systematic reviews assessed using appropriate appraisal tools. An extensive list of potential outcomes was compiled from literature and expert consultations and then ranked by GDG members. The top outcomes were identified for evidence synthesis in three key areas: utility of surveillance in IBD, quality of bowel preparation and use of advanced imaging techniques in colonoscopy for IBD. Risk thresholding exercises determined specific risk levels for different surveillance strategies and intervals. This approach enabled the GDG to establish precise thresholds for interventions based on relative and absolute risk assessments, directly informing the stratification of surveillance recommendations. Significance of effect sizes (small, moderate, large) will guide the final GRADE assessment of the evidence. Ethics and dissemination Ethics approval is not applicable. By integrating clinical expertise, patient experiences and innovative methodologies like risk thresholding, we aim to deliver actionable recommendations for IBD colorectal surveillance. This protocol, complementing the main guidelines, offers GDGs, clinical trialists and practitioners a framework to inform future research and enhance patient care and outcomes.


  • Open Access

    Patients’ and health professionals’ research priorities for chronic pain associated with inflammatory bowel disease: a co-produced sequential mixed methods Delphi consensus study

    by Morris Gordon, Vassiliki Sinopoulou, Roxana Mardare, Mansour Abdulshafea, Ciaran Grafton-Clarke, Jessica Vasiliou

    Objective Chronic pain in inflammatory bowel disease (IBD) is common and detrimental to quality of life. Recent Cochrane reviews identified a multitude of randomised controlled trial interventions, but the certainty of the findings is low or very low. We set out to reach a patient and professional co-produced Delphi consensus on treatment priorities, key outcomes and propose a model for understanding our findings. Methods An online survey was co-produced with Crohn’s and Colitis UK and sent to patients and healthcare professionals in two phases, for prioritisation of treatments and outcome measures. Phase three consisted of four online group interviews, where patients and healthcare professionals discussed the rationale of their choices. Transcripts were combined with the free text data from the Delphi surveys and analysed through a three-phase qualitative technique. Results The phase 1 survey was completed by 128 participants (73 patients, 3 carers and 53 health professionals). Diet was the top priority for both patients (n=26/73, 36.1%) and healthcare professionals (n=29/52, 56.9%). Phase 2 was completed by 68 participants. FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) diet, stress management therapy and relaxation therapy were the top three consensus priorities. Phase 3 group interviews were attended by 13 patients and 5 healthcare professionals. Key themes included: The patient as an individual, beliefs and experiences, disease activity influencing therapy choice, accessibility barriers and quality of life. Conclusion Low FODMAP diet, followed by psychological therapies were the highest-rated research priorities for healthcare professionals and patients. Funding bodies and researchers should consider these findings, alongside the model for understanding our findings, when making research decisions.


  • Open Access

    How do we define therapy-resistant constipation in children aged 4–18 years old? A systematic review with meta-narrative synthesis

    by Vassiliki Sinopoulou, Morris Gordon, Shaman Rajindrajith, Watshala Hathagoda, Aditi Bhupendra Rane, Anita Sedghi, Merit Tabbers, Carlo Di Lorenzo, Miguel Saps, Marc A Benninga

    Background Therapy-resistant constipation often is a frustrating clinical entity recognised by the persistence of infrequent and painful bowel movements faecal incontinence and abdominal pain despite intensive treatment. It is important to clearly define therapy-resistant constipation before children are subjected to invasive diagnostic and therapeutic procedures. Aim To conduct a systematic review determining how paediatric interventional studies define therapy-resistant constipation. Method We searched CENTRAL, MEDLINE, Embase, WHO ICTR and ClinicalTrials.gov. Studies that included patients with therapy-resistant constipation were identified. Data were extracted on criteria used for defining therapy-resistant constipation and reported using a meta-narrative approach highlighting areas of convergence and divergence in the findings. Results A total of 1553 abstracts were screened in duplicate, and 47 studies were included in the review. There were at least seven definitions used in the paediatric literature to define medically resistant constipation. The term intractable was used in 24 articles and 21 used the term refractory to describe therapy-resistant constipation. Out of them, only 14 articles have attempted to provide an explicit definition including a predefined time and prior therapy. There were 10 studies without a clear definition for therapy-resistant constipation. The duration before being diagnosed as therapy-resistant constipation varied from 1 months to 2 years among studies. Seven studies employed the Rome criteria (Rome III or Rome IV) to characterising constipation while five adopted the Rome III and European and North American paediatric societies definition of paediatric gastroenterology, hepatology and nutrition guideline of management of constipation in children. Conclusion The current literature has no explicit definition for therapy-resistant constipation in children. There is a need for a detailed consensus definition to ensure consistency of future research and to avoid unnecessary and maybe even harmful, invasive diagnostic and therapeutic interventions.